Site Map
Pages
- About us
- Blood cancer information
- Carers and friends
- For healthcare professionals
- Myeloma Awareness
- Real stories
- The blood cancer journey
- Types of blood cancer
- Amyloidosis
- Aplastic anaemia
- Blood cancer and COVID-19
- Childhood blood cancers
- Leukaemia
- Lymphoma
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Adult T-cell lymphoma
- Anaplastic large cell lymphoma
- Burkitt’s lymphoma
- Diffuse large B-cell lymphoma
- Double hit lymphoma
- Follicular lymphoma
- Lymphoblastic lymphoma
- Mantle cell lymphoma
- Mucosa-associated lymphoid tissue lymphoma
- Nodal marginal zone lymphoma
- Non-Hodgkin lymphoma diagnosis
- Non-Hodgkin lymphoma treatment
- Peripheral T-cell lymphoma
- Primary central nervous system lymphoma
- Skin lymphomas
- Small lymphocytic lymphoma
- Myelodysplastic syndromes (MDS)
- Myeloma
- Myeloproliferative neoplasms (MPN)
- Understanding your blood
- Waldenstrom’s macroglobulinaemia (WM)
- World Lymphoma Awareness Day
- COVID-19 vaccinations
- Disclaimer
- Donate
- Get involved
- Home
- How we can help
- Accommodation services
- About our accommodation services
- Bridgestone Australia Village (Adelaide)
- Building of Hope (Melbourne)
- Clem Jones – Sunland Village (Brisbane)
- ESA Village (Brisbane)
- Herston Village (Brisbane)
- John James Village (Canberra)
- NSW Accommodation
- Policies and reimbursements
- Queensland Freemasons Village (Townsville)
- Village Green Apartments (Brisbane)
- Western Australia
- Advocacy and policy
- Assessment and referral services
- Emotional support services
- Grief and bereavement support services
- Health and wellbeing support services
- Information and education services
- Practical support services
- Support groups
- Support research with your own blood cancer story
- Transport services
- Accommodation services
- Lifeblood Newsletter
- Maintaining an exercise routine
- Make a donation
- National Research Program
- National Strategic Action Plan for Blood Cancer
- New Normal Same Cancer
- News
- Notification statement
- OCP Consultation Process
- Online Support Group Details
- Privacy
- Recycle your containers for blood cancer
- Research
- Current funding opportunities
- National Research Program
- Cancer Australia PdCCRS recipients
- Developing a new drug a as a novel therapeutic strategy for aggressive leukaemia in children
- Developing a new targeted therapy with minimal side effects and toxicity to improve the outcome of childhood AML
- Developing new models for drug testing to understand the biology and mechanisms of drug resistance in AML
- Developing new tests to identify which individuals with smouldering myeloma are at risk of developing myeloma
- Harnessing the power of the microbiome to prevent GvHD in children after a stem cell transplant
- Increasing the efficiency while decreasing toxicity of myeloma therapies
- Studying the interaction between bone and leukaemia cells to improve treatment outcomes in childhood leukaemia
- Using immunotherapy to improve lymphoma outcomes
- Using novel combination therapy to increase the chances of cure for childhood AML
- Clinical trials
- PhD scholarship recipients
- Dr Khai Li Chai: 2020 recipient
- Dr Liesl Butler: 2020 recipient
- Identifying subclones in early phase MPN that drive progression and leukaemic transformation
- Investigating the mechanisms by which Tp53 prevents the development of leukaemia, lymphoma
- T-cell immunotherapy for B-cell malignancies and viral infections
- Targeting the cancer-immune crosstalk in acute myeloid leukaemia (AML)
- Using antifungal treatments to prevent infection in people with blood cancers and those undergoing bone marrow transplants
- Using genetic and molecular technologies to better understand follicular lymphoma
- Strategic Ecosystem Partnership Grant recipients
- Characterisation of a novel DCAF factor as a blood cancer therapy
- Deep profiling of ALL and myeloma for targeted therapies
- Developing state-of-the art molecular genetic testing in cancer diagnosis and monitoring
- Establishing a new prognostic score for Follicular Lymphoma to rationalise therapeutic decision-making and improve patient outcomes
- Multiomic analysis in Waldenstrom’s Macroglobulinemia
- Precision Medicine in acute lymphoblastic leukaemia
- The Centre for Blood Transplant and Cell Therapy
- The role of the bone marrow microenvironment in the myeloma plasma cell dormancy and reactivation – toward a cure for myeloma
- Understanding the process of progression from MDS to acute leukaemia
- Translational Research Program Grant recipients
- Beyond Azacitidine: Investigating new therapeutic strategies for the treatment of MDS
- Improving therapy for CRLF2-rearranged Ph-like acute lymphoblastic leukemia
- Optimising azacitidine (AZA) responsiveness in MDS, CMML and AML
- Personalized Metabolic Targeting of Epigenetic AML Mutations
- Targeting deregulated epigenetic mechanisms in B-cell lymphomas
- Therapeutic targeting of IRF4 to treat multiple myeloma
- Cancer Australia PdCCRS recipients
- Past research
- Boosting the immune system response
- Double discovery – game changer in quest to cure leukaemia
- Graft v Host disease
- Investigating factors that may cause genetic changes in leukaemia
- New drug combination turbo charges attack against cancer
- Novel drug for treatment of Burkitt’s lymphoma
- Research project archive
- Researchers identify gene that could lead to better understanding of MDS
- Targeting stem cells in myeloproliferative disorders
- Research in action
- siobhan
- Site map
- Terms of use
- Thanks for sharing your story
- Update your details
- Blood Cancer Awareness Month Resources
- Cancer Australia Research Grants
- PhD Scholarships Program
- My Life Counts